GIA
TRIL

Gladstone Institutional Advisory’s Trillium Therapeutics Inc. TRIL Stock Holding History

Gladstone Institutional Advisory’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,542
Closed -$228K – 614
2021
Q2 		$228K Buy
23,542
+101
+0.4% +$951 0.03% 462
2021
Q1 		$252K Buy
+23,441
New +$290K 0.04% 350
2020
Q4 		– Sell
-10,150
Closed -$144K – 326
2020
Q3 		$144K Buy
+10,150
New +$101K 0.03% 257

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Gladstone Institutional Advisory's TRIL Position: Q3 2021 in Review

Gladstone Institutional Advisory sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 23,542 shares — an estimated $228K sold.

Gladstone Institutional Advisory first reported a position in TRIL in Q3 2020 and held it in 3 quarters. The position peaked at $252K in Q1 2021. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Gladstone Institutional Advisory reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 23,542 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $228K.
  • Gladstone Institutional Advisory first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 3 quarters.
  • Gladstone Institutional Advisory's Trillium Therapeutics Inc. position peaked at $252K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2021, filed 15 Nov 2021.